HBF reports revenue growth with expanding membership outside WA

September 25, 2023 Other Health

This is a preview of subscriber content

Subscribe now to continue reading.

HBF, Australia’s fifth-largest private health insurer, has released its 2023 annual report with a 7.5 per cent increase in group revenue to $1.995 billion. …

Subscribe now to continue reading.

Latest Video

New Stories

Medicines Australia gains a new voice with Vertex joining the association
December 11, 2025 - - Latest News
BMS marks 70 years in Australia with renewed commitment to innovation and access
December 11, 2025 - - Latest News
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - - Latest News
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech
OncoSil announces first UK patient treated with its pancreatic cancer treatment
December 10, 2025 - - Australian Biotech

HBF reports revenue growth with expanding membership outside WA

This is a preview of subscriber content

Latest Video

Most Read

Health Department clarifies PBAC plan after confusion over paediatric access to biologics

If this was the plan, why wasn't it included in the response to questions last week?

Regulators approve longevity molecule NMN for use in therapeutic goods

Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy

Australian breakthrough uncovers genetic trigger for severe macular degeneration

New Stories

Medicines Australia gains a new voice with Vertex joining the association

BMS marks 70 years in Australia with renewed commitment to innovation and access

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN

OncoSil announces first UK patient treated with its pancreatic cancer treatment

Sign In

HBF reports revenue growth with expanding membership outside WA

This is a preview of subscriber content

Latest Video

Most Read

Health Department clarifies PBAC plan after confusion over paediatric access to biologics

If this was the plan, why wasn't it included in the response to questions last week?

Regulators approve longevity molecule NMN for use in therapeutic goods

Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy

Australian breakthrough uncovers genetic trigger for severe macular degeneration

Follow Us

New Stories

Medicines Australia gains a new voice with Vertex joining the association

BMS marks 70 years in Australia with renewed commitment to innovation and access

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN

OncoSil announces first UK patient treated with its pancreatic cancer treatment